Back to today’s briefing

Story perspectives

GC Biopharma Launches Pfizer's Paxlovid: 86% Hospitalization Reduction

6/2/2025

36 4

Summary

Story summary

GC Biopharma has launched the distribution of Pfizer’s oral Covid-19 antiviral, Paxlovid, in Korea, marking a significant transition to private sector supply. With Pfizer Korea overseeing its commercial distribution, this game-changing medication, priced at 941,940 won per pack, boasts an impressive 86% reduction in hospitalization risk when administered early.

1 of 1

Story summary

GC Biopharma has launched the distribution of Pfizer’s oral Covid-19 antiviral, Paxlovid, in Korea, marking a significant transition to private sector supply. With Pfizer Korea overseeing its commercial distribution, this game-changing medication, priced at 941,940 won per pack, boasts an impressive 86% reduction in hospitalization risk when administered early.